Prime Medicine, Inc. (NASDAQ:PRME) is featured in the 12 Best Genomics Stocks to Invest In. The company announced the New England Journal of Medicine publication of PM359 data for its experimental stem cell therapy for p47phox chronic granulomatous condition. LifeSci Capital started covering PRME with an Outperform rating and $6 price target.

Prime Medicine, Inc. (NASDAQ:PRME) focuses on genetic medicines using Prime Editing technology. The company is working on one-and-done gene editing treatments for conditions like cystic fibrosis and Wilson’s disease with extensive unmet demand. LifeSci Capital is optimistic about PRME’s potential in Wilson’s disease and alpha-1 antitrypsin deficiency.

While PRME shows investment potential, some AI stocks may offer greater upside with less downside risk. For a highly undervalued AI stock with potential benefits from Trump-era tariffs and the onshoring trend, check out the best short-term AI stock.

Disclosure: None.

Read more at Yahoo Finance: Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data